6.
Van Rie A, Whitfield M, De Vos E, Scott L, da Silva P, Hayes C
. Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020; 75(5):1123-1129.
PMC: 8453393.
DOI: 10.1093/jac/dkz564.
View
7.
Chakravorty S, Simmons A, Rowneki M, Parmar H, Cao Y, Ryan J
. The New Xpert MTB/RIF Ultra: Improving Detection of and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017; 8(4).
PMC: 5574709.
DOI: 10.1128/mBio.00812-17.
View
8.
Torrea G, Ng K, Van Deun A, Andre E, Kaisergruber J, Ssengooba W
. Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance. Sci Rep. 2019; 9(1):11826.
PMC: 6694172.
DOI: 10.1038/s41598-019-48401-z.
View
9.
Kumar S, Stecher G, Tamura K
. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol. 2016; 33(7):1870-4.
PMC: 8210823.
DOI: 10.1093/molbev/msw054.
View
10.
Andres S, Hillemann D, Rusch-Gerdes S, Richter E
. Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother. 2013; 58(1):590-2.
PMC: 3910775.
DOI: 10.1128/AAC.01752-13.
View
11.
Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P
. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015; 372(12):1181-2.
DOI: 10.1056/NEJMc1413930.
View
12.
CANETTI G, Fox W, Khomenko A, MAHLER H, Menon N, Mitchison D
. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969; 41(1):21-43.
PMC: 2427409.
View
13.
Dookie N, Khan A, Padayatchi N, Naidoo K
. Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field. Front Microbiol. 2022; 13:775030.
PMC: 8988194.
DOI: 10.3389/fmicb.2022.775030.
View
14.
Shah N, Grace Lin S, Barry P, Cheng Y, Schecter G, Desmond E
. Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013. Open Forum Infect Dis. 2016; 3(3):ofw150.
PMC: 5047429.
DOI: 10.1093/ofid/ofw150.
View
15.
Bernardelli A, Morcillo N, Loureiro J, Quse V, Davenport S
. In vitro susceptibility testing of Mycobacterium tuberculosis complex strains isolated from seals to antituberculosis drugs. Biomedica. 2004; 24 Supp 1:85-91.
View
16.
Li M, Lu J, Lu Y, Xiao T, Liu H, Lin S
. Mutations and Effects on Rifampin Resistance in . Infect Drug Resist. 2021; 14:4119-4128.
PMC: 8502021.
DOI: 10.2147/IDR.S333433.
View
17.
Rigouts L, Nolasco O, de Rijk P, Nduwamahoro E, Van Deun A, Ramsay A
. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2006; 45(1):252-4.
PMC: 1828994.
DOI: 10.1128/JCM.01489-06.
View
18.
Liu Y, Sun Y, Zhang X, Zhang Z, Xing Q, Ren W
. Evaluation of the frequency of mutation genes in multidrug-resistant tuberculosis (MDR-TB) strains in Beijing, China. Epidemiol Infect. 2021; 149:e21.
PMC: 8057498.
DOI: 10.1017/S0950268820003131.
View
19.
Ahmad S, Mokaddas E
. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2013; 7(2):75-91.
DOI: 10.1016/j.jiph.2013.09.001.
View
20.
Shivekar S, Kaliaperumal V, Brammacharry U, Sakkaravarthy A, Vidya Raj C, Alagappan C
. Prevalence and factors associated with multidrug-resistant tuberculosis in South India. Sci Rep. 2020; 10(1):17552.
PMC: 7567814.
DOI: 10.1038/s41598-020-74432-y.
View